Compare SNY & SYK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNY | SYK |
|---|---|---|
| Founded | 1994 | 1941 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.4B | 141.2B |
| IPO Year | N/A | N/A |
| Metric | SNY | SYK |
|---|---|---|
| Price | $49.34 | $363.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 15 |
| Target Price | $61.50 | ★ $434.64 |
| AVG Volume (30 Days) | ★ 2.3M | 1.7M |
| Earning Date | 10-24-2025 | 01-27-2026 |
| Dividend Yield | ★ 3.23% | 0.92% |
| EPS Growth | ★ 105.93 | N/A |
| EPS | ★ 8.67 | 7.61 |
| Revenue | ★ $53,890,648,839.00 | $24,381,000,000.00 |
| Revenue This Year | $2.37 | $12.01 |
| Revenue Next Year | $6.51 | $8.59 |
| P/E Ratio | ★ $11.25 | $47.83 |
| Revenue Growth | N/A | ★ 10.95 |
| 52 Week Low | $44.62 | $329.16 |
| 52 Week High | $60.12 | $406.19 |
| Indicator | SNY | SYK |
|---|---|---|
| Relative Strength Index (RSI) | 46.53 | 45.54 |
| Support Level | $48.89 | $364.49 |
| Resistance Level | $50.43 | $374.10 |
| Average True Range (ATR) | 0.73 | 6.22 |
| MACD | -0.15 | 0.03 |
| Stochastic Oscillator | 19.29 | 30.67 |
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.